Matthias L Cavassini - Infectious Diseases

Author Information

Matthias L Cavassini is affiliated with the Division of Infectious Diseases at the University Hospital Lausanne, located in Lausanne, Switzerland. His expertise lies in the field of infectious diseases, with a significant focus on HIV research.

Research Contributions

Matthias L Cavassini has made substantial contributions to the field of infectious diseases, particularly in the study of HIV. His recent work includes investigating the use of anticholinergic medication in elderly HIV patients with neurocognitive impairment, the impact of latent tuberculosis infection on type 2 diabetes mellitus in HIV-infected individuals, and the safety and immunogenicity of tuberculosis vaccines. His research also explores the prevalence of clonal hematopoiesis in people living with HIV, the characterization of trans women in the context of HIV, and the development of long-acting antiretrovirals for HIV management and prevention.

Aliases

Matthias L Cavassini is also known by several variations of his name in academic publications, including M Cavassini, M L Cavassini, and M. Cavassini. These aliases reflect the different formats in which his name appears across various publications.

Publication and Citation Metrics

Metric	Value
Total Citation Count	17,136
h-index	66
Total Paper Count	460

Publications:

Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.

DOI: 10.1093/jac/dkab386

Year: 2022

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.

DOI: 10.1093/jac/dkab324

Year: 2022

Impact of Latent Tuberculosis Infection on the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study.

DOI: 10.1093/infdis/jiac054

Year: 2022

Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics.

DOI: 10.1097/QAI.0000000000002949

Year: 2022

Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

DOI: 10.1038/s41598-021-04308-2

Year: 2022

Safety and Immunogenicity of a Candidate Tuberculosis Vaccine ChAdOx1-85A Delivered by Aerosol Versus Intramuscular Route in Healthy Adults in a Phase 1, Double-Blind Randomized Controlled Trial

DOI: 10.2139/ssrn.4051471

Year: 2022

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.

DOI: 10.1093/jac/dkab324

Year: 2022

Identifying and Characterizing Trans women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.

DOI: 10.1093/cid/ciab628

Year: 2021

A phylogeny-aware GWAS framework to correct for heritable pathogen effects on infectious disease traits

DOI: 10.1101/2021.11.22.21266687

Year: 2021

Coronary Artery Disease-associated and Longevity-associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living with HIV: The Swiss HIV Cohort Study.

DOI: 10.1093/cid/ciab521

Year: 2021

What are the Legal and Ethical Considerations?

What are the common misconceptions about condoms?

How Can Quarantine be Effectively Implemented?

How Can Yellow Fever Be Prevented?

How Can Hepatitis B be Prevented?

How Can Malaria Be Prevented?

How Can We Target the Apicoplast for Treatment?

What is Public Health?

How is Rabies Diagnosed?

How Are Blood Tests Conducted?

Partnered Content Networks

Relevant Topics